Moderna (MRNA)
NASDAQHealth CareBiotechnologySnapshot 2026-07-07
$79.77-2.48%
Close 2026-07-07 · 1-day change
Reading MRNA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MRNA free→NASDAQHealth CareBiotechnologySnapshot 2026-07-07
Reading MRNA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MRNA free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. MRNA is currently navigating a period of loss-making while targeting revenue growth, but recent performance has been weak and the overall thesis state is mixed.
The market appears to be pricing in a stretched valuation compared to peers, with an expectations gap indicating that some growth is anticipated. However, the low model confidence suggests that investors may be cautious about future performance.
Fundamentals may continue to struggle in the near term, as MRNA has reported erratic earnings surprises and faces elevated risks. Management's focus on revenue growth and expense management shows mixed progress, which could impact future results.
The thesis hinges on MRNA's ability to meet its revenue growth targets and manage operating expenses effectively. Additionally, the performance of sector bellwethers like VRTX, REGN, and ARGX will be crucial in determining the overall healthcare sector momentum.
Over the next 1 to 3 years, MRNA's performance will depend on its execution against growth targets and external sector influences. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. Moderna's expanding mRNA platform shows growth potential. However, it recently missed earnings expectations, which raises concerns. Competition from other vaccine stocks also poses a threat.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: New funding could support cash flow and future projects.
Confirms:New government funding agreements or grants are announced.
Disproves:No new funding announcements in the next quarter.
Why it matters: Having enough cash is key. It helps fund projects and keeps operations running.
Confirms:Cash, cash equivalents, and investments increase from $7.5 billion in Q1 2026.
Disproves:Cash, cash equivalents, and investments decrease further from $7.5 billion in Q1 2026.
Why it matters: Earnings results will show if Moderna is on track for its 10% revenue growth target in 2026.
Confirms:Q2 2026 earnings report shows revenue growth of at least 5% year over year.
Disproves:Q2 2026 earnings report shows revenue decline or growth below 5% year over year.
Why it matters: Progress in the CMV vaccine trial may show growth in Moderna's projects and money sources.
Confirms:Positive interim results came from the Phase 3 study of the CMV vaccine (mRNA-1647).
Disproves:Delays or negative results came from the Phase 3 study of the CMV vaccine.
Why it matters: Having strong cash is important for funding operations and growth.
Confirms:Cash position reported stable or increasing in Q2.
Disproves:Cash position was reported to be down in Q2.
Why it matters: If mRNA-1010 gets approved, it will be a big step for Moderna's flu vaccine.
Confirms:The FDA grants approval for mRNA-1010 before the August 5 PDUFA date.
Disproves:The FDA delays approval of mRNA-1010 past the August 5 date.
Why it matters: Data from the RSV vaccine study may affect Moderna's growth and market position.
Confirms:Positive interim results came from the Phase 2/3 study of the RSV vaccine (mRNA-1345).
Disproves:Negative results or delays came from the Phase 2/3 study of the RSV vaccine.
Why it matters: Controlling operating costs is important for making more money. High costs can show bigger problems.
Confirms:Operating costs drop from $1,777 million in Q1 2026.
Disproves:Operating costs rise from $1,777 million in Q1 2026.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.